Trials / Unknown
UnknownNCT02588937
Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 76 (estimated)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the antiviral activity and safety of EntecaBell ODT. in chronic hepatitis B Patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EntecaBell ODT. 0.5mg | |
| DRUG | Baraclude Tab. 0.5mg |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2017-02-01
- Completion
- 2017-06-01
- First posted
- 2015-10-28
- Last updated
- 2016-12-14
Locations
9 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02588937. Inclusion in this directory is not an endorsement.